Vertex Pharmaceuticals Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for VRTX, updated each market day.
VRTX AI Sentiment
AI predicts Vertex Pharmaceuticals Inc stock is likely to increase over the next 10 market days.
Prediction date: Oct. 9, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
Sector
Exchange
Market Cap
$128,438,788,627
Cap Tier
Employees
6,400
Headquarters
BOSTON, MA
Listed Since
July 31, 1991
Website
VRTX Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
VRTX Volatility
Vertex Pharmaceuticals Inc has shown low price volatility over the last 5 trading days. Low volatility suggests steady price action with smaller daily moves.
